Credit Suisse Ag Kinnate Biopharma Inc. Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Shares
3 transactions
Others Institutions Holding KNTE
# of Institutions
63Shares Held
32.9MCall Options Held
94.7KPut Options Held
802K-
Foresite Capital Management Iv, LLC Larkspur, CA9.67MShares$013.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.01MShares$00.48% of portfolio
-
Foresite Capital Management V, LLC Larkspur, CA3.53MShares$015.38% of portfolio
-
Viking Global Investors LP1.82MShares$00.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.08MShares$00.0% of portfolio
About Kinnate Biopharma Inc.
- Ticker KNTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,145,600
- Description
- Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...